Effect of Supplemental Lutein and Zeaxanthin on Serum, Macular Pigmentation, and Visual Performance in Patients with Early Age-Related Macular Degeneration
| Autor: | Yang-Mu Huang, Xiao-Ming Lin, Xian-Rong Xu, Hong-Liang Dou, Fei-Fei Huang, Zhiyong Zou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Lutein medicine.medical_specialty endocrine system Visual acuity Article Subject genetic structures media_common.quotation_subject Visual Acuity lcsh:Medicine Placebo General Biochemistry Genetics and Molecular Biology law.invention Contrast Sensitivity chemistry.chemical_compound Macular Degeneration Randomized controlled trial law Zeaxanthins Ophthalmology medicine Macular Pigment Contrast (vision) Humans media_common Aged General Immunology and Microbiology business.industry lcsh:R food and beverages General Medicine Macular degeneration Middle Aged medicine.disease eye diseases Zeaxanthin chemistry Clinical Study Quality of Life Female sense organs medicine.symptom business |
| Zdroj: | BioMed Research International BioMed Research International, Vol 2015 (2015) |
| ISSN: | 2314-6141 2314-6133 |
| Popis: | Purpose. To compare the 2-year effect of multiple doses of lutein/zeaxanthin on serum, macular pigmentation, and visual performance on patients with early age-related macular degeneration (AMD).Methods. In this randomized, double-blinded, and placebo-controlled trial, 112 early AMD patients randomly received either 10 mg lutein, 20 mg lutein, a combination of lutein (10 mg) and zeaxanthin (10 mg), or placebo daily for 2 years. Serum concentration of lutein/zeaxanthin, macular pigment optical density (MPOD), visual functions including best-spectacle corrected visual acuity (BCVA), contrast sensitivity (CS), flash recovery time (FRT), and vision-related quality of life (VFQ25) was quantified.Results. Serum lutein concentration and MPOD significantly increased in all the active treatment groups. Supplementation with 20 mg lutein was the most effective in increasing MPOD and CS at 3 cycles/degree for the first 48 weeks. However, they both significantly increased to the same peak value following supplementation with either 10 mg or 20 mg lutein during the intervention. No statistical changes of BCVA or FRT were observed during the trial.Conclusions. Long-term lutein supplementation could increase serum lutein concentration, MPOD, and visual sensitivities of early AMD patients. 10 mg lutein daily might be an advisable long-term dosage for early AMD treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|